Rchr
J-GLOBAL ID:202001004324257553   Update date: Jul. 19, 2024

Kagoya Yuki

カゴヤ ユウキ | Kagoya Yuki
Affiliation and department:
Job title: Professor
Research field  (1): Immunology
Research theme for competitive and other funds  (6):
  • 2023 - 2026 Development of CAR-NK cell therapy with durable response through genetic manipulation
  • 2022 - 2025 The determination of T-cell fate by different tumor antigens and prevention of post-operative recurrence of lung cancer
  • 2021 - 2023 Development of a combinatorial approach of antibody therapeutics and adoptive immunotherapy for cancer
  • 2020 - 2023 Generation of long-surviving antitumor T cells by genetic modification for optimal adoptive immunotherapy
  • 2019 - 2021 Development of a chimeric synthetic receptor to suppress T cell exhaustion for use in adoptive cancer immunotherapy
Show all
Papers (48):
  • Toshiaki Yoshikawa, Yusuke Ito, Zhiwen Wu, Hitomi Kasuya, Takahiro Nakashima, Sachiko Okamoto, Yasunori Amaishi, Haosong Zhang, Yang Li, Tetsuya Matsukawa, et al. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell Reports Medicine. 2024. 5. 5. 101526-101526
  • Nakashima T, Kagoya Y. Current progress of CAR-T-cell therapy for patients with multiple myeloma. Int J Hematol. 2024
  • Hitomi Kasuya, Haosong Zhang, Yusuke Ito, Toshiaki Yoshikawa, Takahiro Nakashima, Yang Li, Tetsuya Matsukawa, Satoshi Inoue, Yuki Kagoya. High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions. International Immunology. 2024. 36. 7. 353-364
  • Yuki Kagoya. Cytokine signaling in chimeric antigen receptor T-cell therapy. International Immunology. 2024. 36. 2. 49-56
  • Yusuke Ito, Satoshi Inoue, Takahiro Nakashima, Haosong Zhang, Yang Li, Hitomi Kasuya, Tetsuya Matsukawa, Zhiwen Wu, Toshiaki Yoshikawa, Mirei Kataoka, et al. Epigenetic profiles guide improved CRISPR/Cas9-mediated gene knockout in human T cells. Nucleic Acids Research. 2024. 52. 1. 141-153
more...
MISC (9):
  • 籠谷 勇紀. CAR-T細胞療法開発の現状と今後の展望. 血液内科(科学評論社). 2024. 88. 2. 176-182
  • 籠谷 勇紀. 血液がんを標的としたCAR-T細胞療法の現状と課題. 炎症と免疫(先端医学社). 2023. 31. 4. 283-288
  • 籠谷 勇紀. 多発性骨髄腫に対するCAR-T細胞療法の研究開発動向. 血液内科(科学評論社). 2023. 86. 5. 676-681
  • 籠谷 勇紀. キメラ抗原受容体遺伝子改変T細胞療法の改良. 腫瘍内科(科学評論社). 2023. 31. 4. 462-467
  • 籠谷 勇紀. PRDM1遺伝子ノックアウトによる長期生存型抗腫瘍T細胞の作製. 血液内科(科学評論社). 2022. 85. 5. 753-758
more...
Lectures and oral presentations  (48):
  • CAR-T細胞の前臨床評価における ヒト化マウスの活用
    (2024)
  • Regulation of cytokine signaling for improved adoptive immunotherapy
    (The 42nd Sapporo International Cancer Symposium 2024)
  • Reinforcing CAR-T cell function through metabolic regulation
    (2024)
  • Adoptive immunotherapy for autoimmune diseases
    (2024)
  • Understanding the mechanisms of resistance to CAR-T cell therapy at the molecular level
    (The 1st International Symposium on Cancer Immunology and Immunotherapy 2024)
more...
Education (2):
  • 2009 - 2013 The University of Tokyo Graduate School of Medicine
  • 2001 - 2007 The University of Tokyo Faculty of Medicine
Professional career (1):
  • 博士 (医学) (東京大学)
Work history (8):
  • 2023/01 - 現在 Keio University School of Medicine Division of Tumor Immunology, Institute for Advanced Medical Research Professor
  • 2020/04 - 2022/12 Nagoya University Graduate School of Medicine Division of Cellular Oncology, Department of Cancer Diagnostics and Therapeutics Adjunct Professor
  • 2019/10 - 2022/12 Aichi Cancer Center, Research Institute Division of Immune Response Chief
  • 2018/06 - 2019/09 The University of Tokyo Faculty of Medicine University Hospital Assistant Professor
  • 2014/06 - 2018/05 Princess Margaret Cancer Centre Tumor Immunotherapy Program Research Fellow
Show all
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page